ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug

Ascendis Pharma received a positive European Medicines Agency opinion for its achondroplasia drug TransCon CNP, which is already FDA-approved in the U.S., with final European Commission approval expected in late 2026 and launch in Germany in early 2027. Despite this, the company's shares declined slightly, reflecting investor expectations and limited current commercial impact.

This Wire brief sits within Fusion42's coverage of Biotech.